Dedicated to Our Patients

We empower patients and are dedicated to helping restore active lifestyles.
William R. Gallivan, Jr., MD

Hip Replacement Options

Which Hip Replacement Option is Best for Me?

There are a variety of anatomic hip implant options that help match your natural anatomy. New technologies are available today that may improve the longevity of implants and may increase the motion in your hip.

Cormet Hip Resurfacing

Hip resurfacing is a procedure that uses a metal cap over the hip ball and that may conserve more bone than traditional hip replacement procedures. This large diameter cap may reduce the risk of dislocation and often provides a more natural performance than total hip replacement.1 Hip resurfacing is not for everyone; it is more appropriate for active patients with osteoarthritis and good bone quality.

Total Hip Replacement

For Improved Motion

Larger femoral heads are designed to allow for more motion and enhanced joint stability than smaller femoral heads. Stryker's anatomic femoral heads are larger in size, similar to the top of your femur, so they are designed for natural hip performance.

For Reduced Wear

Advanced bearing materials have demonstrated significant wear reduction in laboratory testing. 2,3 Technologies such as ceramic-on-ceramic and X3® polyethylene are designed to reduce wear. This decrease in wear may extend the life of your hip implant.

Total Hip Replacement vs. Cormet Hip Resurfacing

Hip resurfacing is most appropriate for active patients with:

  • Good bone quality
  • Osteoarthritis

When is Total Hip Replacement a Better Choice?

Hip resurfacing is not recommended for patients with the following conditions:

  • Active or suspected infection in or about the hip joint;
  • Poor bone quality which your surgeon feels could not support the implant;
  • Multiple cysts;
  • Any known allergy to metal (e.g., jewelry);
  • Extreme overweight (overload on device that would lead to failure);
  • Skeletal immaturity;
  • Women in child-bearing years;
  • Weak immune system due to disease or certain medications (e.g., corticosteroids);
  • Kidney failure.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Stryker and X3. All other trademarks are trademarks of their respective owners or holders.

For Hip Resurfacing indications, contraindications and risk information, see the Cormet Patient Labeling.

This material is intended for US distribution only.

Cormet Hip Resurfacing System is manufactured by Corin.
Distributed exclusively by Stryker Orthopaedics in the USA.

Cormet is a registered trademark of Corin PLC.

References:

1. PMA P050016, Summary of Safety & Effectiveness.
2. Stryker Orthopaedics Test Report: RD-03-082.
3. Stryker Orthopaedics Trident Acetabular Inserts made of X3 UHMWPE (unsterilized), 721-00-32E, show a 97% reduction in volumetric wear rate versus the same insert fabricated from N2\Vac gamma sterilized UHMWPE,620-00-32E. The insert tested was 7.5mm thick with an inner diameter of 32mm. Testing was conducted under multi-axial hip joint simulation for 5 million cycles using a 32mm CoCr articulating counterface and calf serum lubricant. X3 UHMWPE Trident Acetabular Inserts showed a net weight gain due to fluid absorption phenomena but yielded a positive slope and wear rate in linear regression analysis. Volumetric wear rates were 46.39 ± 11.42mm3/106 cycles for N2\Vac gamma sterilized UHMWPE inserts and 1.35 ± 0.68mm3/106 cycles for X3 UHMWPE (unsterilized) Trident Acetabular Inserts. Although in-vitro hip wear simulation methods have not been shown to quantitatively predict clinical wear performance, the current model has been able to reproduce correct wear resistance rankings for some materials with documented clinical results. a,b,c

a. Wang, A., et al., Tribology International, Vol. 31, No. 1-3:17-33, 1998.
b. Essner, A., et al., 44th Annual Meeting, ORS, New Orleans, Mar. 16-19, 1998:774.
c. Essner, A., et al., 47th Annual Meeting, ORS, San Francisco, Feb. 25-28, 2001:1007.